ID Source | ID |
---|---|
PubMed CID | 6480937 |
CHEMBL ID | 3251700 |
MeSH ID | M0295125 |
Synonym |
---|
(2s)-2-[[(2s,3r)-3-amino-2-hydroxy-4-(4-nitrophenyl)butanoyl]amino]-4-methyl-pentanoic acid |
nitrobestatin |
(2s)-2-[[(2s,3r)-3-amino-2-hydroxy-4-(4-nitrophenyl)butanoyl]amino]-4-methylpentanoic acid |
CHEMBL3251700 , |
bdbm50010219 |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1845880 | Antimalarial activity against Plasmodium falciparum D10 incubated for 48 hrs by [3H]hypoxanthine incorporation assay | 2021 | Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4 | Metalloaminopeptidases of the Protozoan Parasite |
AID1845879 | Inhibition of recombinant Plasmodium falciparum A-M17 assessed as inhibition constant using H-Leu-NHMec as substrate | 2021 | Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4 | Metalloaminopeptidases of the Protozoan Parasite |
AID1133938 | Inhibition of rat liver aminopeptidase B using 0.2 mM L-leucine-beta-naphthylamide by colorimetry | 1977 | Journal of medicinal chemistry, Apr, Volume: 20, Issue:4 | Synthesis and structure-activity relationships of bestatin analogues, inhibitors of aminopeptidase B. |
AID1133940 | Retardation factor, Rf value of the compound using BuOH-AcOH-H20 at 4:1:1 ratio by ninhydrin | 1977 | Journal of medicinal chemistry, Apr, Volume: 20, Issue:4 | Synthesis and structure-activity relationships of bestatin analogues, inhibitors of aminopeptidase B. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 1 (16.67) | 18.7374 |
1990's | 1 (16.67) | 18.2507 |
2000's | 3 (50.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (16.67) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.74) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (16.67%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (83.33%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |